SCHEMBL1609206

SCHEMBL1609206

CCOC(=O)c1cc2cc(OC)c(O)cc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
KDM4E B2RXH2 5/20 0.50
HPGD P15428 4/20 0.50
AKR1B1 P15121 3/20 0.50
HSD17B10 Q99714 3/20 0.50
CA12 O43570 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
GAA P10253 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CA1 P00915 2/20 0.50
MCL1 Q07820 2/20 0.50
CA13 Q8N1Q1 2/20 0.50
GLA P06280 2/20 0.50
CYP1A2 P05177 1/20 0.50
AMY1A P0DUB6 1/20 0.50
CASP1 P29466 1/20 0.50
RECQL P46063 1/20 0.50
CASP7 P55210 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768249 0.91 AKR1B1 (0.48) ALDH1A1KDM4EHPGDAKR1B1CA12
SCHEMBL22323777 0.85 LMNA (0.47) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL19782558 0.85 AKR1B1 (0.43) ALDH1A1KDM4EHPGDAKR1B1CA12
SCHEMBL6478488 0.83 MAOB (0.64) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL18397754 0.83 AKR1B1 (0.63) ALDH1A1KDM4EAKR1B1HSD17B10MEN1
SCHEMBL3640452 0.81 AKR1B1 (0.50) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL4804407 0.80 AKR1B1 (0.49) ALDH1A1KDM4EHPGDAKR1B1HSD17B10
SCHEMBL1609793 0.79 F2 (0.53) ALDH1A1KDM4EHPGDCASP1CASP7
SCHEMBL3809016 0.78 F2 (0.52) ALDH1A1KDM4EHPGDCASP1CASP7
Hydrogen Sulfide SCHEMBL3809014 0.78 F2 (0.52) ALDH1A1KDM4EHPGDCASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318785-B2 Pharmaceutical compounds ORION CORPORATION (FI) 2012-11-27 US disclosed
US-20110086852-A2 PHARMACEUTICAL COMPOUNDS ORION CORPORATION (FI) 2011-04-14 US disclosed
EP-1910325-B1 NEW PHARMACEUTICAL COMPOUNDS ORION CORP (FI) 2010-10-06 EP disclosed
US-20090209532-A1 PHARMACEUTICAL COMPOUNDS ORION CORPORATION (FI) 2009-08-20 US disclosed
EP-1910325-A2 NEW PHARMACEUTICAL COMPOUNDS ORION CORPORATION (FI) 2008-04-16 EP disclosed
WO-2007010085-A2 NEW PHARMACEUTICAL COMPOUNDS ORION CORPORATION (FI) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209532-A1 PHARMACEUTICAL COMPOUNDS COMT, CYP2C19, UGT1A1 ALDH1A1 65/4885KDM4E 2512/4885HPGD 163/4885
US-20110086852-A2 PHARMACEUTICAL COMPOUNDS COMT, CYP2C19, CYP3A4 ALDH1A1 233/4885KDM4E 594/4885HPGD 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.